Canada Pension Plan Investment Board Acquires 36,300 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Canada Pension Plan Investment Board raised its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 417.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,000 shares of the company's stock after acquiring an additional 36,300 shares during the period. Canada Pension Plan Investment Board owned approximately 0.10% of Pacira BioSciences worth $848,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in PCRX. XTX Topco Ltd acquired a new stake in Pacira BioSciences in the 4th quarter worth $523,000. Barclays PLC increased its stake in Pacira BioSciences by 4.4% during the fourth quarter. Barclays PLC now owns 423,221 shares of the company's stock valued at $7,972,000 after acquiring an additional 17,744 shares during the period. Sterling Capital Management LLC raised its holdings in Pacira BioSciences by 779.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock valued at $26,000 after acquiring an additional 1,208 shares in the last quarter. Capital Fund Management S.A. lifted its position in shares of Pacira BioSciences by 34.6% in the 4th quarter. Capital Fund Management S.A. now owns 175,225 shares of the company's stock worth $3,301,000 after acquiring an additional 45,016 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in shares of Pacira BioSciences during the 4th quarter worth approximately $190,000. 99.73% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently commented on PCRX. HC Wainwright raised their target price on Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research report on Tuesday, April 8th. Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 price objective on shares of Pacira BioSciences in a report on Tuesday, April 8th. Truist Financial raised shares of Pacira BioSciences from a "sell" rating to a "hold" rating and upped their target price for the company from $8.00 to $25.00 in a research note on Thursday, January 30th. Royal Bank of Canada restated a "sector perform" rating and set a $18.00 price target on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Finally, Barclays upped their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $26.67.

Pacira BioSciences Stock Down 0.4 %

Shares of Pacira BioSciences stock traded down $0.10 on Wednesday, hitting $26.90. The company had a trading volume of 838,311 shares, compared to its average volume of 985,537. Pacira BioSciences, Inc. has a twelve month low of $11.16 and a twelve month high of $31.67. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. The stock has a 50-day moving average of $24.58 and a 200-day moving average of $21.68. The firm has a market capitalization of $1.24 billion, a P/E ratio of -13.25 and a beta of 0.71.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.